Table 1.
Baseline Characteristics Including Demographics; Framingham Risk Factors; and Measures of Coronary, Aortic, and Valvular Calcification
| Imaging Cohort | |
|---|---|
| Participants, na | 3217 |
| Age, y, | 50±10 |
| Female, n (%) | 1639 (50.9) |
| Hypercholesterolemia, n (%) | 21.4% |
| On statin treatment, n (%) | 11.5% |
| Total cholesterol, mg/dL | 196.7±35.0 |
| HDL cholesterol, mg/dL | 53.8±16.6 |
| Hypertension, n (%) | 42.9 |
| On hypertensive treatment, n (%) | 522 (16.2) |
| Systolic blood pressure, mm Hg | 122±18 |
| Diastolic blood pressure, mm Hg | 77±20 |
| Diabetes mellitus, n (%) | 169 (5.3) |
| Body mass index, kg/m2 (mean) | 27.7±5.9 |
| Obese (>30 kg/m2) | 861 (26.8) |
| Smoking, n (%) | |
| Current, n (%) | 401 (12.5) |
| Former, n (%) | 1219 (37.9) |
| Never, n (%) | 1597 (49.6) |
| Framingham Risk Score | |
| Mean | 6.6±6 |
| Low/intermediate/high, n (%)b | 1926 (59.9)/1166 (36.2)/124 (3.9) |
| Vascular and valvular calcifications | |
| CAC | |
| Prevalence, n (%) | 1351 (42.5) |
| 25th/50th/75th/95th percentile | 0/0/32.3/502.9 |
| 0, 1 to 100, 101 to 300, >300, n (%) | 1831 (57.5), 822 (25.8), 270 (8.5), 259 (8.1) |
| AAC | |
| Prevalence, n (%) | 1637 (51.2) |
| 25th/50th/75th/95th percentile | 0/1.2/368/4099 |
| TAC | |
| Prevalence, n (%) | 660 (20.8) |
| 25th/50th/75th/95th percentile | 0/0/0/559 |
| AVC | |
| Prevalence, n (%) | 475 (14.9) |
| 25th/50th/75th/95th percentile | 0/0/0/75 |
| MVC | |
| Prevalence, n (%) | 225 (7.0) |
| 25th/50th/75th/95th percentile | 0/0/0/18 |
All values shown are mean±SD except when otherwise specified. AAC indicates abdominal aorta calcification; AVC, aortic valve calcification; CAC, coronary artery calcification; HDL, high‐density lipoprotein; MVC, mitral valve calcium; TAC, thoracic aorta calcification.
a
Without prevalent cardiovascular disease.
b
Framingham Heart Study: low 0% to 6%, intermediate 6% to 20%, high >20%.